



October 8, 2021

Santen to Present Latest Data on STN2000100 (DE-128, MicroShunt)
at 39th ESCRS

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced today that a publication related to the glaucoma surgical device, STN2000100 (DE-128, MicroShunt) will be presented at the 39th Congress of the European Society of Cataract & Refractive Surgeons (39th ESCRS; <https://congress.escrs.org/>) from October 8 to 11, 2021.

STN2000100 has been launched in Europe as *PRESERFLO MicroShunt* and Santen successively filed for marketing approval in Asia. Santen submitted the Premarket Approval (PMA) application in the U.S. In the conference, a presentation of data from a clinical study in the U.S. and Europe, INN-005 (NCT01881425), will be conducted.

In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; <https://www.santen.com/en/news/20210519-1.pdf>).

Presentation topics

Poster #	Title
PP001	Safety Outcomes of MicroShunt Implantation versus Trabeculectomy in Patients with Primary Open-angle Glaucoma

For abstracts, please see the following link;

<https://congress.escrs.org/wp-content/uploads/2021/09/ESCRS-2021-Poster-Cataract.pdf>

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com